New shot may shield cancer patients from dangerous chemo complication
NCT ID NCT07187908
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This study tests a drug called efbemalenograstim alfa to prevent febrile neutropenia (a dangerous drop in white blood cells with fever) in people with solid tumors getting chemotherapy. About 1,076 participants will receive the drug either as a first-time prevention or after a prior low white blood cell event. The goal is to see if it safely reduces the risk of infection and keeps white blood cell counts stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY/SECONDARY PREVENTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Henan cancer hospital
RECRUITINGZhengzhou, Henan, 450003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.